LONDON, April 25, 2014 /PRNewswire/ --
On Thursday, April 24, 2014, the NASDAQ Composite ended at 4,148.34, up 0.52%, the Dow Jones Industrial Average finished the day flat at 16,501.65, and the S&P 500 closed at 1,878.61, up 0.17%. The gains were narrow based as four out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 668.80, down 0.20%, while the index has advanced 0.39% in the last one month. Investor-Edge has initiated coverage on the following equities: Amarin Corp. PLC (NASDAQ: AMRN), United Therapeutics Corp. (NASDAQ: UTHR), Hologic Inc. (NASDAQ: HOLX) and NxStage Medical Inc. (NASDAQ: NXTM). Free technical research on AMRN, UTHR, HOLX and NXTM can be downloaded upon signing up at:
On Thursday, shares in Amarin Corp. PLC fluctuated between $1.60 and $1.66 before ending the session 1.85% higher at $1.65. The company's stock reported a trading volume of 1.14 million shares, much below its three months average volume of 3.03 million shares. Amarin Corp. PLC's shares have advanced 4.43% in the previous three trading sessions. However, the stock has fallen by 6.25% during the last one month and 16.24% on YTD basis. The stock is trading below its 50-day and 200-day moving averages, while Amarin Corp. PLC's 200-day moving average of $3.32 is above its 50-day moving average of $1.78. Moreover, shares of the company have a Relative Strength Index (RSI) of 41.13. Sign up today to read free research on AMRN at:
United Therapeutics Corp.'s stock finished the Thursday's session at $93.50, down 0.14% than the previous day's closing price of $93.63. A total of 1.08 million shares were traded, which was above its three months average volume of 0.86 million shares. The stock moved between $91.02 and $94.68 during the session. Over the last one month and the previous three months United Therapeutics Corp.'s shares have declined 0.65% and 13.06%, respectively. Also, from the beginning of 2014, the company's stock has gone down by 17.32%. The company's shares are trading above their 200-day moving average. Moreover, the stock's 50-day moving average of $97.55 is greater than its 200-day moving average of $89.38. United Therapeutics Corp.'s stock traded at a PE ratio of 28.51 and has an RSI of 45.22. Sign up today to read free research on UTHR at:
On Thursday, Hologic Inc.'s stock recorded a trading volume of 6.04 million shares, much higher than its three months average volume of 2.39 million shares. The stock ended the day at $20.73, which was 1.22% higher than its previous day's closing of $20.48. The stock registered an intraday range of $20.50 and $20.99. Additionally, Hologic Inc.'s shares have lost 2.81% in the last one month and 7.25% on YTD basis. The company's stock is trading below its 50-day and 200-day moving averages, while the 50-day moving average of $21.49 is below the company's 200-day moving average of $21.67. Furthermore, shares of the company have an RSI of 35.28. Sign up today to read free research on HOLX at:
On Thursday NxStage Medical Inc.'s shares edged 2.40% higher, to close the day at $11.95. The stock recorded a trading volume of 0.46 million shares, which was below its three months average volume of 0.59 million shares. The stock vacillated between $11.68 and $12.05 during the session. Over the last three trading sessions and over the past one month, shares in NxStage Medical Inc. have fallen by 2.05% and 8.29%, respectively. However, the stock has surged 19.50% since the start of this year. The stock is trading below its 50-day and 200-day moving averages, while the 50-day moving average of $13.27 is above NxStage Medical Inc.'s 200-day moving average of $12.46. Additionally, the stock has an RSI of 34.48. Sign up today to read free research on NXTM at:
1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is fact checked and produced on a best efforts basis and reviewed by Namrata Maheshwari, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.investor-edge.com.
5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.investor-edge.com.
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.investor-edge.com for consideration.
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Investor-Edge. An outsourced research services provider represented by Namrata Maheshwari, CFA, has only reviewed the information provided by Investor-Edge in this article or report according to the procedures outlined by Investor-Edge. Investor-Edge is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Investor-Edge makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Investor-Edge is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Investor-Edge whatsoever for any direct, indirect or consequential loss arising from the use of this document. Investor-Edge expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Investor-Edge does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.